Zentalis Pharmaceuticals, Inc.
$334.64M- Market cap
- $285.97M
- Debt
- +$82.57M
- Cash
- −$33.90M
Capital structure 78% equity / 22% debt · EV / Revenue 4.96x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ZNTL stock price vs BN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BN's multiple
Needs BN P/S.
Implied fair value · at ZNTL's multiple
Needs Revenue / share.
Metric by metric
Snapshot Sep 4, 4:00 PM ET
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ZNTL FY 2024 (ended Dec 31, 2024) · BN FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 78% equity / 22% debt · EV / Revenue 4.96x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Zentalis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
BROOKFIELD CORPORATION · implied price per share
The ordinary-share to listed-security ratio could not be verified.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.24x
—
Net debt / EBITDA
Leverage against operating earnings
-0.29x
95.68x
Cash and equivalents
Liquid reserves on the balance sheet
$33.90M
$16.24B
Total debt
Interest-bearing obligations outstanding
$82.57M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Arcus Biosciences, Inc.
ZNTL vs RCUS
Repare Therapeutics Inc.
ZNTL vs RPTX
IDEAYA Biosciences, Inc.
ZNTL vs IDYA
Mersana Therapeutics, Inc.
ZNTL vs MRSN
EXELIXIS, INC.
ZNTL vs EXEL
BXP, Inc.
ZNTL vs BXP
SL GREEN REALTY CORP
ZNTL vs SLG
HIGHWOODS PROPERTIES, INC.
ZNTL vs HIW
CBRE GROUP, INC.
ZNTL vs CBRE
JONES LANG LASALLE INC
ZNTL vs JLL
KILROY REALTY CORP
ZNTL vs KRC
$325.77B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.